Concentra®, the nation’s leader in occupational medicine, today announced the opening of a new medical center in Waukegan, ...

JPMorgan analyst Lisa Gill raised the firm’s price target on Concentra (CON) to $30 from $29 and keeps an Overweight rating on the shares.

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

Concentra Group (CON) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Concentra Group (CON) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over the past ...

Fitch Ratings has revised its outlook for Equitable Bank (EQB) to positive from stable, while affirming the bank’s Long-Term Issuer Default Ratings (IDRs) at BB ...

Bank of New York Mellon Corp increased its stake in shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Free Report) by 1,339.5% during the 4th quarter, Holdings Channel.com reports. The firm ...

Concentra Group Holdings Parent Stock Performance Shares of CON opened at $20.63 on Friday. Concentra Group Holdings Parent, Inc. has a 12 month low of $18.89 and a 12 month high of $24.81. The ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...